CSL Behring Japan
CSL Behring is a global biotechnology leader providing a wide range of biopharmaceuticals for rare and serious diseases, including bleeding disorders, primary immunodeficiency, hereditary angioedema, neurodegenerative diseases, and alpha-1 antitrypsin deficiency. The company is committed to developing and delivering innovative biological products to improve the lives of patients worldwide. With a history of over a century in biotechnology, CSL Behring continues to evolve and expand its product portfolio to meet the needs of patients globally. It operates in over 30 countries, with a large plasma collection network, and is part of CSL Limited, a global biopharmaceutical company based in Melbourne, Australia.
Industries
Nr. of Employees
small (1-50)
CSL Behring Japan
Products
Extended half‑life recombinant factor IX (albumin‑fusion)
Intravenous recombinant coagulation factor IX engineered as an albumin‑fusion protein to extend circulating half‑life and allow extended dosing intervals for hemophilia B management.
Single‑chain recombinant factor VIII therapy
Recombinant single‑chain factor VIII designed to improve molecular stability and provide sustained hemostatic activity for prophylaxis and treatment of hemophilia A.
High‑concentration subcutaneous human immunoglobulin (20%)
A 20% human immunoglobulin formulation for subcutaneous administration intended to enable less frequent dosing and at‑home therapy for immunoglobulin replacement.
Monoclonal antibody inhibitor of activated factor XII for prophylaxis
Human monoclonal antibody that inhibits activated factor XII to reduce occurrence of acute hereditary angioedema attacks, formulated for monthly subcutaneous administration.
Gene therapy program for hemophilia B
A gene therapy program targeting hemophilia B intended to provide sustained factor expression as a long‑term treatment option; progressed through regulatory review in major jurisdictions.
Self‑amplifying mRNA vaccine manufactured domestically
Self‑amplifying mRNA vaccine platform product authorized for adult immunization against SARS‑CoV‑2 and domestically manufactured under regulatory authorization.
Extended half‑life recombinant factor IX (albumin‑fusion)
Intravenous recombinant coagulation factor IX engineered as an albumin‑fusion protein to extend circulating half‑life and allow extended dosing intervals for hemophilia B management.
Single‑chain recombinant factor VIII therapy
Recombinant single‑chain factor VIII designed to improve molecular stability and provide sustained hemostatic activity for prophylaxis and treatment of hemophilia A.
High‑concentration subcutaneous human immunoglobulin (20%)
A 20% human immunoglobulin formulation for subcutaneous administration intended to enable less frequent dosing and at‑home therapy for immunoglobulin replacement.
Monoclonal antibody inhibitor of activated factor XII for prophylaxis
Human monoclonal antibody that inhibits activated factor XII to reduce occurrence of acute hereditary angioedema attacks, formulated for monthly subcutaneous administration.
Gene therapy program for hemophilia B
A gene therapy program targeting hemophilia B intended to provide sustained factor expression as a long‑term treatment option; progressed through regulatory review in major jurisdictions.
Self‑amplifying mRNA vaccine manufactured domestically
Self‑amplifying mRNA vaccine platform product authorized for adult immunization against SARS‑CoV‑2 and domestically manufactured under regulatory authorization.
Services
Financial and operational support for investigator‑initiated clinical and translational research aligned with therapeutic focus areas.
Online professional portals providing clinical resources, prescribing information and product resources for appropriate clinical use.
Nationwide logistics and home delivery services to support patients receiving specialty biologic therapies and to improve treatment adherence.
Mobile applications and disease‑specific information websites offering symptom tracking, treatment scheduling, educational content and downloadable emergency resources.
Donations, sponsorships and fellowship funding to support academic meetings, early‑stage research and public education in medicine and pharmacy.
Financial and operational support for investigator‑initiated clinical and translational research aligned with therapeutic focus areas.
Online professional portals providing clinical resources, prescribing information and product resources for appropriate clinical use.
Nationwide logistics and home delivery services to support patients receiving specialty biologic therapies and to improve treatment adherence.
Mobile applications and disease‑specific information websites offering symptom tracking, treatment scheduling, educational content and downloadable emergency resources.
Donations, sponsorships and fellowship funding to support academic meetings, early‑stage research and public education in medicine and pharmacy.
Expertise Areas
- Clinical trial management and registrational programs
- Recombinant biologics design for bleeding disorders
- Plasma collection and fractionation supply chains
- Vaccine platform R&D and manufacturing
Key Technologies
- Recombinant protein therapeutics
- Half‑life extension via fusion constructs (albumin fusion)
- Single‑chain recombinant factor constructs
- Plasma fractionation and purification
News & Updates
Connecting the voices of people living with rare diseases to society, under the slogan 'Connecting the voices of people living with rare diseases.'
A new information site for patients and families about gene therapy.
A new drug for hereditary angioedema approved for use in Japan.
Celebrating a century of innovation and commitment to saving lives with a donation of 100 trees and establishing a $25 million R&D fellowship.
Presentation of data on AFSTYLA® for pediatric and adolescent hemophilia A patients at the World Federation of Hemophilia 2016.
CSL Behring's IDELVION® received FDA approval for hemophilia B treatment, allowing dosing intervals of up to 14 days.
Connecting the voices of people living with rare diseases to society, under the slogan 'Connecting the voices of people living with rare diseases.'
A new information site for patients and families about gene therapy.
A new drug for hereditary angioedema approved for use in Japan.
Celebrating a century of innovation and commitment to saving lives with a donation of 100 trees and establishing a $25 million R&D fellowship.
Presentation of data on AFSTYLA® for pediatric and adolescent hemophilia A patients at the World Federation of Hemophilia 2016.
CSL Behring's IDELVION® received FDA approval for hemophilia B treatment, allowing dosing intervals of up to 14 days.